Filamon

Clinical stage anti-inflammatory drug development

to solve the unmet needs
of an ageing population

Pre-IPO Capital Raise - August 2024

Filamon

Diseases of ageing are overwhelmingly associated with chronic inflammation – a natural response to a lifetime of ‘wear and tear’

The biology of these diseases is complex, typically involving the misbehaviour of dozens, even hundreds, of different genes

Current anti-inflammatory drugs mostly have been designed to target single genes, making them too limited in their actions to provide more than temporary relief of symptoms at best. As the disease progresses, these drugs usually lose their effectiveness

Filamon is developing first-in-class anti-inflammatory drugs that target multiple misbehaving genes

The aim is a family of next generation anti-inflammatory drugs providing more potent and longer-lasting benefits for many of the common age-related diseases.

Age-Related Chronic Inflammatory Disease

Filamon

Filamon is focused on developing the **next generation of anti-inflammatory drugs** for 3 of the most pressing, most under-treated disease states facing an increasingly ageing world

What distinguishes Filamon drugs from the current generation of anti-inflammatory drugs

Filamon



USE CASE – CANCER

Filamon

Five decades of development of chemotherapy, radiotherapy and immunotherapy have bought undoubted survival benefits for cancer patients.

But … not all cancer types have benefited.

And …. regardless of cancer type, once the cancer becomes aggressive and spreads, patients have few effective treatment options.

With the result that cancer remains one of the top 3 causes of death of the elderly.

The one area of cancer therapy that has not progressed in 50 years is in blocking the role of inflammation in cancer.

Inflammation is responsible for the establishment of the **tumour micro-environment (TME),** with the **TME** being the key driver of cancer growth and spread.

Despite this, a drug that successfully shuts down all key aspects of the TME has yet to be developed.

Filamon believes that **inflammation** is the **missing link in cancer therapy** and sees two Filamon drugs offering ground-breaking opportunities to treat this neglected area of cancer.

KS-c2

successfully passes a first-in-human study in patients with advanced prostate cancer.

60 patients to be part of the next Phase I/II study scheduled to commence in 2025. A ground-breaking trial that will test for the first time in cancer patients a drug able to shut down **vimentin-driven ECM and EMT inflammatory processes**

IMP-2

is built on 2 decades of clinical research involving hundreds of cancer patients.

A first-in-class inhibitor (action CONFIDENTIAL) of the inflammatory processes driving cancer growth, the **TME**, metastasis, immune dysfunction and chemo-resistance.

CANCER KS-c2 *Clinical stage*

Filamon

A tumour is ~50% cancer cells.

The other 50% is a wide range of normal cells all hijacked by cancer cells to support cancer growth.

This is the **TUMOUR MICRO-ENVIRONMENT (TME)** and is the result of **INFLAMMATION**.

Current anti-inflammatory drugs have little or no effect on the TME.



The TME is a key Missing Link in cancer treatment

- **KS-c2 is the first vimentin inhibitor to reach the clinic, creating a first-in-class inhibitor of**
- **extracellular matrix formation**
- **epithelial-mesenchymal transition.**

The purpose of the drug is to inhibit the major components of the TME, depriving the cancer cells of their support structure and leaving them more susceptible to the effects of chemotherapy and immunotherapy

CANCER KS-c2 *Clinical stage*

Filamon



KS-c2 works by blocking the activation of proteins including vimentin and EGFR by inflammatory ligands such as hGIIA. The inhibitory effect on EGFR importantly occurs despite common EGFR mutations.

KS-c2 has successfully undergone a first-in-human study in late-stage cancer patients confirming oral bioavailability and safety.

An upcoming adaptive Phase I/II study (ADVICE Study) in up to 60 patients with late-stage cancer will be an important world-first study combining a comprehensive anti-TME drug with standard anti-cancer therapy.

USE CASE – OPHTHAMOLOGY

Filamon

The major cause of blindness in elderly people is neovascular (wet) age-related macular degeneration. This chronic inflammatory disease affects the macular region of the retina, the region responsible for central vision.

Loss of central vision progresses from age of about 60 to eventual blindness.

Current treatment involves the injection directly into the eyeball of anti-inflammatory drugs on a monthly , rest-of-life basis.

The limitations of current treatment are:

- Failure to work in 1 in 3 people
- Slow, rather than stop, disease progression
- Uncomfortable/painful treatment
- Treat-associated side-effects
- Inconvenience/cost of monthly clinic visits.

LK-BT2 is being developed as a **breakthrough oral or eyedropper treatment**.

The Federal Government and UNSW are helping Filamon develop LK-BT2 as a result of its potential to become the market leader in a current **A$15 billion** p.a. **market**



OPHTHAMOLOGY

LK-BT2

Pre-clinical

Filamon



LK-BT2 is the first known inhibitor of the MEK-ERK-FOS-cJUN signaling pathway

LK-BT2 not only inhibits VEGF genes, but also inhibits multiple other pro-inflammatory genes including VCAM-1, ICAM-1, IL-6, IL-1β, CXCL-1, CXCL-3, CXCL-8 and CCL-20.

LK-BT2 in animal models of macular degeneration outperforms the current lead drug, aflibercept, by a factor of up to 3x.

LK-BT2 is a small molecule with the ability to be dosed as an oral pill or eyedropper. Both are under development.



DEMENTIA

Drug discovery

Filamon

WHO Key Facts

- An estimated 55 million people are believed to have dementia worldwide, with ~ 10 million new cases believed added each year.
- Dementia is caused by a variety of diseases and injuries affecting the brain.
- Alzheimer's Disease accounts for 60-70% of all cases of dementia.
- Women are disproportionately affected by dementia, and it is now the major cause of death in older women.
- The cost of caring for dementia patients requiring 24-hour care and supervision is predicted to become a major burden on national health budgets and on families providing at-home care.

Filamon is bringing two unique approaches to the treatment of dementia involving tau pathology based on the following drug actions:

1. Blocking the role of aberrant vimentin behaviour in creating instability of microtubules in brain cells.
2. Blocking the prion-like (mis-folding) behaviour of PrP^{Sc}, tau and amyloid-β.

IP Protection

Filamon



A GROWING PROBLEM

THE SILVER TSUNAMI

The 'silver tsunami' or 'grey wave' has arrived and with it a dramatic rise in the need for medicines for diseases of ageing.

AGEING POPULATION

The WHO states that by 2030, 1 in 6 people globally will be aged 60+, equating to a populus of 1.4 billion. This figure grows to 2.1 billion by 2050, highlighting the growing addressable market and problem.

CHRONIC INFLAMMATION

Most diseases of ageing are driven by chronic inflammation as a response to a lifetime of 'wear and tear.' The underlying disease processes are complex, involving hundreds of different genes.

THE UNMET NEED

Current anti-inflammatory drugs have proved inadequate because they have been designed for simple inflammatory diseases. A new generation of anti-inflammatory drugs is needed to handle this multi-gene complexity.

Fillamon brings a significant breakthrough in the treatment of complex chronic inflammatory diseases, underpinned by significant tertiary research.

FILAMON

has curated three drug platforms that it believes will deliver the required next generation of anti-inflammatory drugs able to block the role of inflammation driving cancer aggression and spread, neurological damage including dementia, and loss of vision due to a range of degenerative eye diseases

KEY PROJECTED UPCOMING CLINICAL MILESTONES



EXECUTIVE SUMMARY

NEWS FLOW

Five R&D programs underway gives rise to a steady stream of news flow starting late-2024 and proceeding through to the projected time of IPO and beyond.

LARGE ADDRESSABLE MARKETS

Every Filamon pipeline drug is targeting large and growing markets all marked by needing more effective treatments, and in some cases, any treatment. Every market is valued in the **US$10s of billions** and is growing as populations age.

MANAGEMENT INCENTIVISED

The founders are converting 60% of their starting equity to Performance Shares linked to meaningful milestones. They only benefit when the Company makes solid progress in both share value and scientific proof-of-concept.

COMPELLING VALUATION

Post-money of $9M reflects less than 20% of the money already spent to progress the three drug platforms to their current state.

CAPITAL STRUCTURE

COMPANY PROFILE	
Existing Shares on Issue	66,501,820
Shares on issue post Conversion	26,082,722
Pre-IPO $3M @ $0.22	13,636,363
Shares on Issue @ Pre-IPO	39,719,085
Pre-IPO Market Cap @ $0.22	$8,738,199

- 40,419,098 ordinary shares belonging primarily to the three founders will be converted into Performance Shares at completion of the Pre-IPO capital raising.
- These shares will vest in two separate, tranches only following IPO completion, being the commencement of a clinical trial and a share price hurdle.

USE OF FUNDS (PRE-IPO)	$	%
Clinical trial batch of KS-c2	1.5	50
Working Capital	0.7	29
ASX Listing Costs	0.5	15
Offer Costs	0.2	6
TOTAL	**$3.0**	**100**

USE OF FUNDS (IPO)*	$	%
Clinical Trials	5.8	48
R&D Studies	2.2	18
Working Capital	3.2	28
Offer Costs	0.8	6
TOTAL	**$12.0**	**100**

* A more detailed cost breakdown is available upon request and will be itemised in the Company Prospectus

IMPORTANT NOTICE AND DISCLAIMER

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the "Presentation"), relates to Filamon Ltd (the "Company") is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the prior written consent of the Company. By attending the meeting where this Presentation is made, or by reading the Presentation, you agree to be bound by the following limitations.

The Presentation may not be used for, or in connection with, any offer to, or solicitation by, any person in any jurisdiction or under any circumstances in which such offer or solicitation would not be authorized or lawful. The Presentation does not constitute or form part of, and should not be constructed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in the Company in any jurisdiction and does not constitute any form of commitment or recommendation on the part of the Company.

This Presentation is not a prospectus, and the Presentation may not be distributed other than in compliance with applicable securities laws and regulations. A prospectus relating to the Company or the contemplated investment has not been and will not be registered under any law or regulation, and any offering of securities in the Company will only be made pursuant to applicable exemptions in any relevant jurisdiction. The Presentation has not been approved or reviewed by any governmental authority or stock exchange in any jurisdiction. The Company has not decided whether to proceed with a transaction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. Prospective investors must solely rely on their own examination of the legal, financial, taxation and other consequences of an investment in the Company. Prospective investors should not treat the contents of the Presentation as an advice relating to legal, taxation or investment matters.

The Company makes no representation or warranty (whether express or implied) as to the correctness or completeness of the information contained herein, and neither the Company nor any of its affiliates, directors, employees or advisors assume any liability connected to the Presentation and/or the statements set out herein. The information included in this Presentation may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its affiliates, directors, employees or advisors provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. This Presentation speaks as of the date hereof and there may have been changes in matters which affect the Company subsequent to the date of this Presentation.

Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation.

The Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Australian law. The courts of Australia shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with the Presentation or related matters.

Filamon

INVESTOR ENQUIRIES

DR GRAHAM KELLY
info@filamon.com
www.filamon.com